| Document |
Document Title |
|
WO/2005/029076A2 |
The present invention relates to a nanoparticle conjugate comprising a nanoparticle conjugated to a plurality of peptides of a substantially similar amino acid sequence, a peptide conjugated to the nanoparticle by means of a Cysteine (C)...
|
|
WO/2005/026733A1 |
A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antib...
|
|
WO/2005/025516A2 |
Methods for the production of monoclonal antibodies specific to conformational epitope(s) of a prefibrilar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g. Alzhe...
|
|
WO/2005/018575A2 |
The present disclosure relates to the field of cellular tumorigenesis and cancer biology. More specifically, the present disclosure relates to tumorigenesis and cancer in estrogen-responsive cell types, including cell types such as testi...
|
|
WO/2005/019243A1 |
A process for increasing the relative abundance of a molecule having a low relative abundance in a test sample.
|
|
WO/2005/018803A1 |
The invention relates to sintered thermoplastic polymer matrices and to the uses of such matrices for the immobilization of peptides and proteins. Preferably, the polymer used is polyethylene.
|
|
WO/2005/016283A2 |
The present invention relates to cell adhesion promoting ('CAP') peptide combinations that promote cell attachment or cell adhesion to culture surfaces that are otherwise cell adhesion resistant 'CAR'. The invention provides combination ...
|
|
WO/2005/016974A1 |
Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic...
|
|
WO/2005/016971A1 |
The invention provides an organic material-immobilizing structure employing new immobilization means, characterized in that at least a part of the surface of the substrate is comprised of one or more members containing silicon oxide, the...
|
|
WO/2005/016949A2 |
Sialic acid reducing units are passivated, for instance by reduction, or by reductive amination or capping. The process is useful for producing chemically inert sialic acid compounds especially polysialic acids for instance of use as exc...
|
|
WO/2005/014792A2 |
Biomaterial are preserved by exposing them to a preservation agent having preservation properties. The biomaterial has at least one transporter that allows uptake of the preservation agent into the biomaterial for loading the biomaterial...
|
|
WO/2005/011607A2 |
The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodim...
|
|
WO/2005/012479A2 |
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to hu...
|
|
WO/2005/012362A1 |
The invention relates to mehtods for producing an arrangement comprising a plurality of layers, whereby an organic layer is formed on a surface of a semiconductor substrate, under the influence of irradiated light, by applying a medium c...
|
|
WO/2005/009363A2 |
The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progr...
|
|
WO/2005/010530A1 |
A protein microarray element comprising: a) a support; b) a gelatin layer containing functional groups capable of binding biological probes; and interposed between the support and the gelatin layer and c) an adhesive interlayer layer cap...
|
|
WO/2005/010151A2 |
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to hu...
|
|
WO/2005/009396A2 |
The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule...
|
|
WO/2005/009217A2 |
The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progr...
|
|
WO/2005/007844A1 |
The invention features a method of identifying, evaluating and screening for compounds or agents for the treatment of disorders involving the Homer signaling pathway in the modulation of immunosupression and neuroprotection. The method i...
|
|
WO/2005/004798A2 |
The present invention provides methods of identifying an agent that inhibits an activity of a lentiviral Vif protein. The present invention provides methods of identifying an agent that increases the level of active APOBEC3G in a cell. T...
|
|
WO2004033488B1 |
The present invention includes methods of producing magnectic na nocrystals by using a biological molecule that has been modified to possess an amino acid oligomer that is capable of specific b inding to a magnectic material.
|
|
WO/2005/005614A2 |
A composition is described to induce simultaneous humoral (B-cell) and cell-mediated (CTL) immune responses against single or multiple antigens of a pathogenic virus bacteria, or cancer cell. Multiple B-cell and T-cell epitopes are ident...
|
|
WO/2004/112727A2 |
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that disp...
|
|
WO/2004/112572A2 |
This invention relates to the diagnosis and/or monitoring of patients with inflammatory diseases or conditions, e.g., immunologic, hematologic, vascular, or infectious diseases or conditions, by determining levels of complement pathway c...
|
|
WO/2004/111259A2 |
Disclosed are compounds of the general formulas: (I), and (II) wherein Y is a moiety capable of being cleaved by a hydrolytic enzyme; L is a detectable label; X is a linking group; Z is a halogen; and R is hydrogen, an alkyl, or a haloge...
|
|
WO/2004/110370A2 |
Methods and materials are provided for isolating swine pestivirus-like virus and for detecting swine pestivirus-like virus infection in animals.
|
|
WO/2004/110390A2 |
Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic proc...
|
|
WO/2004/106497A2 |
Imaged animal models for coronavirus infection are described.
|
|
WO/2004/103159A2 |
The present invention provides methods of modulating the endometrium, including methods for inhibiting pregnancy and methods for treating gynecological bleeding disorders, such as dysfunctional uterine bleeding and endometrial bleeding. ...
|
|
WO/2004/101766A2 |
Mini chaperones and methods of use thereof for the treatment of cancer and other disorders are provided. Also provided are tools to facilitate screening therapeutic agents which have selective binding affinity for GRP94.
|
|
WO/2004/096124A2 |
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
|
|
WO/2004/096831A2 |
The present invention relates to a method of producing a three-dimensional structure of a nanornaterial on a surface comprising the step of (a) contacting said polymer material affixed to (aa) biological filaments with biologically activ...
|
|
WO/2004/097416A1 |
A magnetic substance-biosubstance complex structure comprises a magnetic substance-containing carrier and a biosubstance immobilized on the carrier, the biosubstance being immobilized through a spacer comprising an amino acid sequence on...
|
|
WO/2004/093823A2 |
The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPE...
|
|
WO/2004/093662A2 |
It is to provide a method and a kit for detecting the prognosis of cancer at high accuracy in a simple and rapid manner at low cost. The method is specifically a method for detecting the prognosis of cancer, at least including a step of ...
|
|
WO/2004/094597A2 |
The present invention relates to fluorescent proteins, genes encoding the proteins, and methods for their use. In particular, the invention relates to a fluorescent protein identified as 'Mick', having an excitation maximum of about 492 ...
|
|
WO/2004/092051A2 |
|
|
WO/2004/089977A1 |
By introducing a polymer compound having a primary amino group in its repeating structure onto the surface of a support, the content of the primary amino group usable in immobilization is increased and thus a protein is immobilized at a ...
|
|
WO/2004/089295A2 |
Novel chemistries, methods and assays are described for the rapid detection and measurement of phosphorylation or de-phosphorylation of polypeptides, oligonucleotides or lipids based upon the use of phosphoryl, phosphoroamino or phosphor...
|
|
WO/2004/090542A1 |
A protein array having protein aligned and immobilized in high density and in uniformly oriented form is produced by introducing a polymer compound having primary amino groups in repeating units in a surface of planar substrate so as to ...
|
|
WO/2004/087765A1 |
A titanium dioxide complex capable of distinguishing molecules is obtained by modifying the surface of a fine titanium dioxide particle with a hydrophilic polymer in such a manner that titanium dioxide is bonded via an ester bond to a ca...
|
|
WO/2004/084812A2 |
The present invention is directed to a compound of Formula I wherein R1, R2, R3, R4, R5, R6, W, X, Y, and Z are defined herein. The compounds of the present invention are useful as anticancer agents. Specifically, the compounds are usefu...
|
|
WO/2004/083258A2 |
The present invention provides branched water-soluble polymers that allow two or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated at a single ...
|
|
WO/2004/083807A2 |
Methods to evaluate and rapidly produce and identify polysaccharides, and other sugar structures, having enhanced activities, have been developed. The methods include producing a molecule, e.g., a therapeutic molecule, which includes a f...
|
|
WO/2004/076631A2 |
The present disclosure relates to a biologically active biomatrix composition. In one embodiment, the biomatrix composition is derived from human amnions. The biomatrix is termed HuBiogelTM. The composition of HuBiogelTM closely mimics n...
|
|
WO/2004/075988A2 |
Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal ser...
|
|
WO/2004/076621A2 |
Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also ...
|
|
WO/2004/071462A2 |
The invention provides methods and compositions based on the interaction of TSG101 and VPS28 proteins for treatment of viral infections, including HIV infections. The invention also provides TSG101-VPS28 based methods and compositions fo...
|
|
WO/2004/065547A2 |
The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibod...
|
